+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Otomycosis Drug"

From
Otomycosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Otomycosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Otomycosis is a fungal infection of the ear canal that is caused by a variety of fungi, including Aspergillus, Candida, and Fusarium species. It is a common condition that affects both adults and children. Treatment of otomycosis typically involves the use of antifungal drugs, such as clotrimazole, miconazole, and amphotericin B. These drugs are often used in combination with other treatments, such as topical steroids and antibiotics. In the context of oncology drugs, otomycosis drugs are used to treat fungal infections that can occur in patients undergoing chemotherapy or radiation therapy. These drugs can help reduce the risk of infection and improve the patient's quality of life. They can also help reduce the risk of complications associated with chemotherapy and radiation therapy. Some companies in the otomycosis drug market include Pfizer, Merck, Novartis, and GlaxoSmithKline. These companies produce a variety of antifungal drugs that are used to treat otomycosis. Show Less Read more